Like Aly, Abdul-Rahman also stresses that GLP-1 medications are a treatment for diabetes and obesity, and as such, they do ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

Watch out, Ozempic. Stanford Medicine scientists have discovered a naturally-occurring molecule that rivals the weight-loss ...

GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Coverage of GLP-1s is not necessarily in-your-face obvious. It leads to the conversation of whether we want to pursue weight ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.